Assembly Bio Reports Phase 1b Success in Herpes; Gilead Increases Stake with 2.3M Shares

Assembly Bio; Phase 1b trial; ABI-5366; herpes simplex virus (HSV-2); viral shedding reduction; genital lesion reduction; safety profile; Gilead Sciences; collaboration; stock purchase